| Quantity | 1 mg, 5 mg, 10 mg | 100 mg | 1 mg, 5 mg, 10 mg | 500 µ, g, 1 mg, 5 mg, 10 mg | 500 µ, g, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |
| Description | Ac-IEPD-AMC is a fluorogenic substrate for the determination of protease activity. Ac-IEPD-AMC undergoes hydrolysis and releases the fluorescent product 7-amino-4-methylcoumarin (AMC). AMC is fluorescent under UV light and can emit a fluorescent signal[1] | Apo-Bovine Transferrin refers to iron free Transferrin (HY-P3267), serves as Transferrin receptor ligand and mediates iron release from endothelial cells. Apo-Transferrin indicates an iron deficient environment, can directly bind to hephaestin, which can convert Fe2+ to Fe3+. Apo-Transferrin Apo-Bovine Transferrin refers to iron free Transferrin (HY-P3267), serves as Transferrin receptor ligand and mediates iron release from endothelial cells. Apo-Transferrin indicates an iron deficient environment, can directly bind to hephaestin, which can convert Fe2+ to Fe3+. Apo-Transferrin mediates iron efflux most likely in cooperation with ferroportin 1[1]... Read More | LL-37 amide TFA is a positively charged antimicrobial peptide. LL-37 amide TFA has anticancer activity and can be used for cancer research[1][2] | PACAP (1-27), human, ovine, rat (PACAP 1-27) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor agonist with IC50s of 3 nM, 2 nM and 5 nM for rat PAC1, rat VPAC1 and human VPAC2, respectively[1] | WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)... Read More |